If you’re a foreign entrepreneur, MNC, or global investor exploring a healthcare company setup in India, 2026 presents one of the most strategically favourable windows in decades. India’s healthcare sector is projected to reach $638 billion by 2025–26, driven by rising domestic demand, an ageing population, expanded government health schemes, and a globally competitive pharmaceutical manufacturing ecosystem. For foreigners, NRIs, and international pharma companies, the opportunity is immense — but so is the regulatory complexity.
India’s healthcare and pharmaceutical industry is among the most tightly regulated sectors in the country. Navigating the Foreign Direct Investment (FDI) policy, the Drugs and Cosmetics Act, the Clinical Establishments Act, CDSCO licensing, FEMA compliance, and company incorporation requirements simultaneously requires precise legal and strategic planning.
This guide breaks down everything you need to know about setting up a healthcare or pharma company in India as a foreign national or foreign entity in 2026 — from entity selection and FDI rules to licensing pathways and compliance obligations.
Understanding the Indian Healthcare and Pharma Landscape
India is the world’s largest supplier of generic medicines, supplying over 50% of global vaccine demand and 25% of all UK medicines. The country’s pharmaceutical sector alone accounts for approximately 3.5% of global pharma output by volume. For foreign companies, India offers a unique combination of low manufacturing costs, a skilled English-speaking scientific workforce, an established export infrastructure, and significant domestic market potential.
The healthcare sector in India spans hospitals and diagnostic centres, pharmaceutical manufacturing, medical devices, biotechnology, telemedicine, health-tech, clinical research organisations (CROs), and wellness. Each sub-sector has distinct regulatory requirements, licensing pathways, and FDI treatment.
If you are considering business setup in India for foreign nationals in the healthcare domain, understanding which sub-sector you are entering is the critical first step, as this determines your regulatory stack entirely.
Legal Framework and Regulations Governing Healthcare/Pharma in India
Foreign entities entering India’s healthcare and pharma sector must navigate a multi-layered regulatory framework. The key laws and authorities include:
Company Formation Framework
All company formation in India is governed by the Companies Act, 2013, administered by the Ministry of Corporate Affairs (MCA). Foreign entities can incorporate a Private Limited Company, a Wholly Owned Subsidiary (WOS), a Branch Office, or a Liaison Office.
FDI Policy (2024–2026)
Under the current FDI policy administered by DPIIT:
| Sub-Sector | FDI Route | Permitted Limit |
|---|---|---|
| Greenfield Pharma Manufacturing | Automatic Route | Up to 100% |
| Brownfield Pharma Acquisition | Government Approval Route | Beyond 74% |
| Hospitals & Medical Devices | Automatic Route | Up to 100% |
| Health Insurance | Automatic Route | Up to 74% |
| Clinical Research Organisations | Automatic Route | Up to 100% |
Key Regulatory Authorities
- CDSCO (Central Drugs Standard Control Organisation): Approves drug manufacturing licences, clinical trials, and medical device registration
- State Drug Licensing Authorities: Issue manufacturing and sales licences under the Drugs and Cosmetics Act, 1940
- Ministry of Health & Family Welfare (MoHFW): Policy oversight for hospitals, clinical establishments, and public health
- FSSAI: Relevant for nutraceuticals, health supplements, and food-medicine interface products
- RBI/FEMA: Governs foreign investment inflows, remittances, and repatriation of profits
For pharma-specific licensing support, explore drug manufacturing licence application and clinical trial registration assistance.
Step-by-Step Process: Setting Up a Healthcare/Pharma Company in India
Step 1 — Choose Your Business Entity
The most suitable structures for foreign healthcare investors include:
Private Limited Company (WOS): Recommended for most foreign investors. Allows 100% foreign ownership in greenfield pharma and hospitals. Governed by the Companies Act, 2013. Proceed with private limited company registration.
Branch Office: Suitable for foreign pharma companies wanting a commercial presence without full incorporation. Requires RBI approval. See branch liaison office setup.
LLP: Not available to foreign nationals under the current automatic FDI route for most healthcare sub-sectors. Review LLP registration if your structure qualifies.
Step 2 — Obtain Director Identification Number (DIN) and Digital Signature
All directors, including foreign nationals, must obtain a DIN and Class 3 Digital Signature Certificate (DSC). DIN and DSC registration is the mandatory starting point.
Step 3 — Incorporate the Company with MCA
File SPICe+ form with MCA. A foreign national serving as director must provide notarised and apostilled identity and address proofs from their home country.
Step 4 — RBI/FEMA Compliance for FDI Inflows
Once incorporated, FDI must be reported to RBI within stipulated timelines via the FC-GPR form. Full RBI/FEMA approvals compliance is mandatory before commercial operations.
Step 5 — Sector-Specific Licensing
This is where healthcare diverges from general company setup in India:
- Pharma Manufacturing: Apply for Drug Manufacturing Licence (Form 25/28) from the State Drug Controller. For bulk drugs, apply to CDSCO. Facility must comply with Schedule M (GMP norms).
- Hospitals/Diagnostic Centres: Register under the Clinical Establishments (Registration and Regulation) Act, 2010 with the respective State authority. Explore hospital and diagnostic centre licensing.
- Medical Devices: Register under the Medical Devices Rules, 2017 with CDSCO.
- Health-Tech/Telemedicine: Comply with Telemedicine Practice Guidelines 2020 and the Digital Personal Data Protection Act (DPDPA) 2023. See DPDPA compliance.
Step 6 — GST Registration and Tax Compliance
Healthcare services offered by clinical establishments are exempt from GST, but pharmaceutical manufacturing and medical device supply are taxable. Obtain GST registration immediately post-incorporation and ensure timely GST return filing.
Step 7 — Intellectual Property Protection
Pharmaceutical companies must protect formulations, processes, and brands. File patent applications for novel drug processes and register trademarks for brand names. Trademark registration and patent filing advisory are essential early-stage steps.
Step 8 — Employment Visa and Resident Director
Foreign founders or key managerial personnel require employment visas. India mandates at least one resident director. Employment visa applications and nominee director services resolve these requirements efficiently.
Key Challenges and Practical Issues
1. Multi-Authority Licensing Complexity
Healthcare company setup involves parallel engagement with MCA, RBI, CDSCO, State Drug Authorities, and potentially FSSAI and DPIIT — each with different timelines and documentation standards. Delays in any one window cascade across the entire setup.
2. Brownfield FDI Government Approval Delays
Foreign acquisitions of existing Indian pharma companies beyond 74% require government approval, which can take 3–6 months and involves DPIIT, Ministry of Health, and CCI (Competition Commission of India) scrutiny.
3. Schedule M / GMP Compliance Costs
India’s revised Schedule M (effective 2025) aligns domestic pharma manufacturing with WHO-GMP standards. For foreign companies setting up manufacturing plants, this adds significant infrastructure compliance cost and requires expert regulatory navigation.
4. Data Localisation and DPDPA Compliance
Health-tech and digital health companies must now comply with India’s DPDPA 2023, which mandates stringent consent frameworks, data fiduciary registration, and data localisation requirements for sensitive personal data including health records.
5. Transfer Pricing and International Tax
MNC subsidiaries in pharma frequently face transfer pricing scrutiny from Indian tax authorities on cross-border transactions including royalties, intra-group services, and supply agreements. Robust transfer pricing compliance documentation is non-negotiable. File accurate income tax returns from day one.
6. FEMA Repatriation Restrictions
Profits from Indian subsidiaries can be repatriated, but dividend distribution tax rules, royalty caps, and loan repayment timelines must be structured with FEMA/RBI compliance in mind.
Strategic Insights and Expert Recommendations
1. Choose Greenfield Over Brownfield When Possible
100% FDI via the automatic route is available for greenfield pharma manufacturing — this eliminates government approval delays, gives you full operational control, and allows clean IP ownership structures from inception.
2. Leverage PLI Scheme Benefits
India’s Production Linked Incentive (PLI) scheme for pharmaceuticals and medical devices offers significant financial incentives for qualifying manufacturers. Foreign companies are eligible. Engage PLI scheme guidance early to structure your manufacturing investment around these incentives.
3. Consider SEZ or EOU Status
Setting up in a Special Economic Zone (SEZ) or as an Export Oriented Unit (EOU) offers customs duty exemptions, GST benefits, and simplified export compliance. This is particularly advantageous for generic drug manufacturers targeting export markets. Explore SEZ unit registration compliance and EOU licensing.
4. Register Under Startup India If Eligible
Innovative health-tech and biotech ventures may qualify for Startup India recognition, unlocking tax exemptions, faster IP processing, and government procurement preference. See Startup India registration.
5. Protect IP Before Market Entry
India follows the “first to file” principle for patents and trademarks. File your drug process patents, device patents, and brand trademarks before entering the Indian market. IP due diligence and licensing is a strategic priority, not an afterthought.
6. Build Robust Corporate Governance from Day One
Healthcare companies in India face enhanced scrutiny from regulators, investors, and international audit bodies. Invest early in corporate governance compliance, proper board composition, and accounting and internal auditing systems.
For country-specific guidance, foreign investors can also explore dedicated resources such as setting up from the USA, UK, Germany, Singapore, or Australia.
Conclusion
Setting up a healthcare or pharma company in India as a foreign investor in 2026 is a high-reward proposition when approached with the right legal and regulatory framework. The combination of a 100% FDI automatic route in greenfield pharma, a massive domestic healthcare demand, government incentives like PLI, and India’s unmatched position in global generic drug supply makes this one of the most compelling emerging market entry opportunities globally.
However, the multi-layered compliance requirements — from CDSCO drug licences to FEMA compliance, Schedule M GMP adherence, DPDPA obligations, and transfer pricing documentation — demand expert guidance from the outset. Every decision you make in the first 90 days of your healthcare company setup in India shapes your regulatory standing, tax efficiency, and long-term operational scalability.
Startup Solicitors LLP provides end-to-end legal, regulatory, and compliance support for foreign healthcare and pharma companies entering India. From incorporation and FDI structuring to drug licensing, IP protection, and ongoing governance, our team navigates the complexity so you can focus on growth.
To begin your healthcare company setup in India, connect with our experts today.
Frequently Asked Questions (FAQs)
Q1. Can a 100% foreign-owned company set up a pharmaceutical manufacturing unit in India?
Yes. Under India’s current FDI policy, 100% foreign direct investment is permitted in greenfield pharmaceutical manufacturing through the automatic route, meaning no prior government approval is required. The company must comply with CDSCO licensing requirements and Schedule M GMP norms before commencing production.
Q2. What is the difference between greenfield and brownfield FDI in Indian pharma?
Greenfield FDI involves establishing a new pharmaceutical facility from scratch, permissible at 100% under the automatic route. Brownfield FDI involves acquiring or investing in an existing Indian pharma company. Beyond 74% in brownfield cases requires government approval through the Foreign Investment Facilitation Portal administered by DPIIT.
Q3. What licences does a foreign company need to manufacture drugs in India?
A foreign-owned entity manufacturing drugs in India requires a Drug Manufacturing Licence from the State Drug Controller (Form 25 for allopathic drugs), compliance with Schedule M under the Drugs and Cosmetics Act, CDSCO approval for new drugs or medical devices, and GST registration. FSSAI registration is additionally required for nutraceuticals and health supplements.
Q4. Is a resident Indian director mandatory for a foreign-owned healthcare company?
Yes. Under Section 149(3) of the Companies Act, 2013, every company incorporated in India must have at least one director who has stayed in India for a total period of at least 182 days in the previous calendar year. Foreign founders typically appoint a professional nominee director to fulfil this requirement.
Q5. How long does it take to set up a pharma company in India as a foreign national?
Company incorporation typically takes 15–25 working days. Drug manufacturing licences from State Authorities may take an additional 3–6 months, depending on facility inspection schedules. Total time from decision to operational readiness for a pharmaceutical manufacturer is typically 9–18 months, subject to facility readiness and regulatory compliance.